Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2025 07:00 ET | Source: SNS Insider pvt ltd

Elastography Imaging Market Size to Reach USD 5.88 Billion by 2032, Driven by Rising Demand for Non-Invasive Diagnostics - SNS Insider

Austin, Texas, Dec. 20, 2025 (GLOBE NEWSWIRE) -- Elastography Imaging Market Size & Growth Analysis: According to SNS Insider, the Elastography Imaging Market size was valued at USD 3.27...
November 07, 2025 06:00 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
October 14, 2025 07:00 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B
September 05, 2025 16:05 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 22, 2025 07:00 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
August 11, 2025 16:01 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
May 29, 2025 16:01 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 22, 2025 20:57 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
May 22, 2025 16:02 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
May 22, 2025 16:01 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

Gyre's Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Liver Fibrosis Trial